Intermittent Claudication

1
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
Ad2/HIF-1α/VP16Phase 21 trial
Active Trials
NCT00117650Completed289Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiAd2/HIF-1α/VP16

Clinical Trials (1)

Total enrollment: 289 patients across 1 trials

NCT00117650SanofiAd2/HIF-1α/VP16

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Start: Feb 2005Est. completion: Mar 2010289 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space